Heritage Investors Management Corp trimmed its stake in shares of Chemours Co (NYSE:CC) by 1.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 125,483 shares of the specialty chemicals company’s stock after selling 1,530 shares during the quarter. Heritage Investors Management Corp owned approximately 0.08% of Chemours worth $2,270,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. DNB Asset Management AS grew its position in Chemours by 1.0% during the 4th quarter. DNB Asset Management AS now owns 648,601 shares of the specialty chemicals company’s stock worth $11,733,000 after acquiring an additional 6,711 shares during the last quarter. FNY Investment Advisers LLC lifted its stake in shares of Chemours by 650.0% in the 4th quarter. FNY Investment Advisers LLC now owns 2,250 shares of the specialty chemicals company’s stock valued at $40,000 after purchasing an additional 1,950 shares during the period. Kenmare Capital Partners L.L.C. purchased a new position in shares of Chemours in the 3rd quarter valued at approximately $214,000. Man Group plc lifted its stake in shares of Chemours by 652.9% in the 3rd quarter. Man Group plc now owns 100,134 shares of the specialty chemicals company’s stock valued at $1,496,000 after purchasing an additional 86,834 shares during the period. Finally, Parametric Portfolio Associates LLC lifted its stake in shares of Chemours by 117.3% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 625,674 shares of the specialty chemicals company’s stock valued at $9,348,000 after purchasing an additional 337,725 shares during the period. Institutional investors and hedge funds own 76.22% of the company’s stock.
CC has been the subject of a number of research analyst reports. Cfra upgraded Chemours from a “hold” rating to a “buy” rating in a research note on Wednesday, November 6th. UBS Group lowered their target price on Chemours from $19.00 to $14.50 and set a “neutral” rating for the company in a research note on Wednesday, October 2nd. SunTrust Banks raised their target price on Chemours to $20.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th. ValuEngine upgraded Chemours from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Finally, Royal Bank of Canada restated a “hold” rating and issued a $19.00 target price on shares of Chemours in a research note on Sunday, December 22nd. Nine investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $23.15.
Chemours (NYSE:CC) last announced its quarterly earnings data on Monday, November 4th. The specialty chemicals company reported $0.59 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.56 by $0.03. The business had revenue of $1.39 billion during the quarter, compared to analysts’ expectations of $1.40 billion. Chemours had a return on equity of 58.38% and a net margin of 7.24%. The firm’s quarterly revenue was down 14.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.49 earnings per share. As a group, equities research analysts predict that Chemours Co will post 2.37 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Monday, December 16th. Shareholders of record on Friday, November 15th were issued a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 5.49%. The ex-dividend date of this dividend was Thursday, November 14th. Chemours’s payout ratio is 17.64%.
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide under the Ti-Pure and BaiMax brands for various applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride window profiles, laminate papers used for furniture and building materials, and coated papers and paperboards used for packaging.
Featured Article: How can you know how many shares are floating?
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.